news
Lilly discontinues development of evacetrapib due to insufficient efficacy
12 October 2015 | By Victoria White
Lilly has said that it will conclude studies of evacetrapib for the treatment of high-risk atherosclerotic cardiovascular disease...
List view / Grid view
Eli Lilly & Company
news
Lilly acquires rights to hypoglycaemia rescue treatment
12 October 2015 | By Victoria White
Intranasal glucagon, currently in Phase III trials, uses a glucagon nasal powder formulation that is delivered in an emergency situation...
news
Abemaciclib gets Breakthrough Therapy Designation
8 October 2015 | By Victoria White
The FDA has granted Breakthrough Therapy Designation to abemaciclib for patients with refractory HR+ advanced or metastatic breast cancer...
news
Baricitinib superior to methotrexate in rheumatoid arthritis
Lilly and Incyte have announced positive top-line results of a Phase 3 study evaluating the safety and efficacy of baricitinib in moderately-to-severely active rheumatoid arthritis (RA).
news
Ramucirumab improves progression-free survival in bladder cancer trial
28 September 2015 | By Victoria White
Median progression-free survival was 5.4 months on the ramucirumab-docetaxel arm as compared to 2.8 months for patients treated with docetaxel alone...
news
Abasaglar provides similar safety and efficacy to Lantus
15 September 2015 | By Victoria White
Data from secondary analyses of Phase III trials show Abasaglar (insulin glargine) demonstrated safety and efficacy outcomes similar to Lantus in diabetes...
news
Synjardy tablets receive FDA approval for adults with type 2 diabetes
27 August 2015 | By Nick Jackson
Synjardy approval was based on multiple clinical trials showing reductions in blood glucose versus placebo...
news
Jardiance demonstrates CV risk reduction in type 2 diabetes
20 August 2015 | By Victoria White
Boehringer Ingelheim and Lilly have announced positive top-line results from a clinical study investigating cardiovascular (CV) outcomes for Jardiance...
news
Lilly to end contract with UCSD for A4 Alzheimer’s study
5 August 2015 | By Victoria White
Lilly has notified UCSD of its intent to end its contract with the University for the management of the Alzheimer's disease A4 study...
news
Florbetapir scans help with patient diagnosis and management
23 July 2015 | By Victoria White
New data shows that knowledge of amyloid status as determined by Florbetapir F 18 Injection imaging altered diagnosis and management of patients...
news
Data suggests Lilly’s solanezumab slows progression of mild Alzheimer’s
22 July 2015 | By Victoria White
Lilly has announced results suggesting that solanezumab slows the progression of Alzheimer's in patients with mild disease...
news
Lilly Diabetes launches Android version of Glucagon Mobile app
15 July 2015 | By Victoria White
Lilly has released an Android version of its Glucagon Mobile application designed for caregivers and healthcare providers who support people with diabetes...
news
Lilly issues statement on FDA Advisory Committee review of necitumumab
10 July 2015 | By Victoria White
Lilly has issued a statement in response to the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee’s ongoing review of necitumumab...
news
Lilly’s NSCLC drug necitumumab shows risk of blood clots
8 July 2015 | By Victoria White
Lilly’s NSCLC drug, necitumumab, has raised concerns with the FDA after trial data suggested that the drug might increase the likelihood of fatal clots...
news
UK court rules in favour of Lilly in Alimta vitamin regimen patent lawsuit
26 June 2015 | By Victoria White
The UK Court of Appeal has ruled in favour of Lilly in the Actavis v. Eli Lilly and Company Alimta vitamin regimen patent lawsuit...
